Rhumbline Advisers Monte Rosa Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 52,468 shares of GLUE stock, worth $369,899. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,468
Previous 47,925
9.48%
Holding current value
$369,899
Previous $179,000
55.31%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding GLUE
# of Institutions
83Shares Held
43.9MCall Options Held
141KPut Options Held
31.2K-
Nea Management Company, LLC Timonium, MD7.69MShares$54.2 Million3.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.6MShares$46.5 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.79MShares$40.8 Million0.46% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$34.7 Million0.28% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$18.7 Million0.55% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $329M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...